Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarkers of Pre-COPD Lung Function Trajectories in Middle Age: A Prospective Study From 1st to 6th Decade.

Respirology (Carlton, Vic.)·2026

Same author

Reply: An index of maximal expiratory flow-volume curve with different features related to central and peripheral concavity.

ERJ open research·2026

Same author

Parental smoke exposure before age 15 years and offspring asthma trajectories from ages 7 to 53 years.

ERJ open research·2026

Same author

Concavity of the maximal expiratory flow-volume curve, and incidence of COPD and respiratory symptoms: a population-based cohort study.

ERJ open research·2026

Same author

Paradigm shifts in asthma: what is old is new again.

The Lancet. Respiratory medicine·2025

Same author

The role of epigenetic regulation in idiopathic pulmonary fibrosis.

American journal of physiology. Lung cellular and molecular physiology·2025

Search research articles

Related Experiment Videos

Microsomal epoxide hydrolase is not associated with COPD in a community-based sample.

Melanie C Matheson¹, Joan Raven, E Haydn Walters

¹Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia.

|June 15, 2007

Summary

Genetic variations in the EPHX1 gene, specifically exon 3 and 4 polymorphisms, do not appear to increase the risk of developing chronic obstructive pulmonary disease (COPD). This study found no association between EPHX1 variations and COPD or its related phenotypes.

Related Experiment Videos

Area of Science:

Genetics
Pulmonology
Environmental Health

Background:

Microsomal epoxide hydrolase (EPHX1) metabolizes cigarette smoke components.
EPHX1 gene polymorphisms are investigated as potential modifiers of smoking-related lung diseases like COPD.
Previous studies linking EPHX1 and COPD have faced concerns regarding genotyping accuracy.

Purpose of the Study:

To investigate the influence of single nucleotide polymorphisms (SNPs) in the EPHX1 gene on chronic obstructive pulmonary disease (COPD) and intermediate phenotypes.
To address potential genotyping errors present in prior research.
To clarify the role of EPHX1 in the development of respiratory diseases.

Main Methods:

Genotyping of EPHX1 exon 3 and exon 4 polymorphisms in 1,232 participants.
Selection of 72 COPD cases and 220 control subjects based on spirometry and respiratory health.
Utilized multiple methods for careful genotyping to ensure accuracy.

Main Results:

No significant association was found between EPHX1 exon 3 polymorphism and COPD risk.
No significant association was found between EPHX1 exon 4 polymorphism and COPD risk.
No EPHX1 haplotypes were associated with an increased risk of any COPD phenotype.

Conclusions:

The EPHX1 exon 3 and exon 4 polymorphisms are unlikely to be strong risk factors for COPD.
Findings suggest that EPHX1 gene variations do not play a significant role in the development of COPD.
The accuracy of previous studies reporting positive associations is questioned, indicating a likely absence of a strong link between EPHX1 and respiratory disease.